ARK Invest sharply increased its exposure to CRISPR Therapeutics during the recent market pullback, purchasing around 281,000 shares valued at nearly $14.82 million on March 11, 2026. The acquisition followed a sharp decline in CRISPR’s share price after the company disclosed a significant private capital raise.
The recent purchase occurred after CRISPR Therapeutics’ stock fell 10%, prompted by its $350 million private placement announcement. ARK Invest’s move reflects its ongoing “buy the dip” approach to high-conviction positions. As of this transaction, CRISPR Therapeutics comprises the second-largest holding across ARK’s ETF portfolios, with a 4.49% overall weighting and approximately $500 million in associated assets.
ARK has a history of building its position in CRISPR Therapeutics, having increased its stake by 7.5% during the last quarter of 2025. While the gene-editing firm reports negative operating margins and remains pre-revenue, the investment firm appears confident in its financial stability. CRISPR Therapeutics maintains a current ratio of 13.32 and a debt-to-equity ratio of 0.11.
To support its portfolio adjustments, ARK Invest executed sales in other areas. These included the divestiture of 21,505 Teradyne shares for about $6.47 million, marking a reduction in exposure to the semiconductor equipment sector. The investment firm also continued decreasing its positions in 10x Genomics, shedding more than 72,000 shares across its ETFs. Additional trimming involved Standard BioTools and a lowered stake in Brera Holdings.
Elsewhere, ARK diversified by purchasing 25,000 shares in the 3iQ Solana Staking ETF for $173,042, expanding into the digital asset space. The firm also started a small position in GeneDx Holdings Corp, adding 6,828 shares.